Center for Translational Research in Hematological Malignancies

Research output

Research output per year 1991 2009 2011 2012 2013 2014 2015 2018 2019 2021 2022 2023

• 9301 Citations
• 176 Article
• 11 Chapter
• 11 Review article
• 4 Editorial
• 2 More
  • 1 Comment/debate
  • 1 Letter

Research output per year

Research output per year

Search results

• 2023

  Isolation of adoptively transferred CD8⁺ T cells in mouse tumor tissues for lipid peroxidation detection

  Xiao, L. & Yi, Q., Mar 17 2023, In: STAR Protocols. 4, 1, 101945.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lipid Peroxidation 100%
  • C11-BODIPY(581-591) 80%
  • Lipid 73%
  • T-Lymphocytes 66%
  • Cytometry 37%
• 2022

  ALCAM regulates multiple myeloma chemoresistant side population

  Wang, F., Dan, Z., Luo, H., Huang, J., Cui, Y., Ding, H., Xu, J., Lin, Z., Gao, Y., Zhai, X., Yang, Y., Qu, Y., Zhang, L., Chen, F., Wang, Q., Wang, X., Feng, Y., Liu, T., Yi, Q., Niu, T., & 1 othersZheng, Y., Feb 10 2022, In: Cell Death and Disease. 13, 2, p. 136 136.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Activated-Leukocyte Cell Adhesion Molecule 100%
  • Multiple Myeloma 59%
  • Population 23%
  • Epidermal Growth Factor 19%
  • Drug Resistance 9%
  3 Scopus citations

• A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors

  Su, P., Xiao, L., Ye, L., Wang, Z., Xiong, W., Wang, Q., Ma, X., Xian, M., Yang, M., Zu, Y., Pingali, S. R., Qian, J. & Yi, Q., May 7 2022, In: Journal of Hematology and Oncology. 15, 1, p. 55 55.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • lysophosphatidic acid 100%
  • Proteasome Inhibitors 89%
  • Multiple Myeloma 73%
  • Oxidative Phosphorylation 16%
  • Apoptosis 13%
  2 Scopus citations

• IL-9/STAT3/fatty acid oxidation-mediated lipid peroxidation contributes to Tc9 cell longevity and enhanced antitumor activity

  Xiao, L., Ma, X., Ye, L., Su, P., Xiong, W., Bi, E., Wang, Q., Xian, M., Yang, M., Qian, J. & Yi, Q., Apr 1 2022, In: Journal of Clinical Investigation. 132, 7, e153247.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Interleukin-9 100%
  • Lipid Peroxidation 64%
  • Longevity 62%
  • Fatty Acids 59%
  • Ferroptosis 29%
  22 Scopus citations

• Loss of miR-31-5p drives hematopoietic stem cell malignant transformation and restoration eliminates leukemia stem cells in mice

  Zhu, B., Zhong, W., Cao, X., Pan, G., Xu, M., Zheng, J., Chen, H., Feng, X., Luo, C., Lu, C., Xiao, J., Lin, W., Lai, C., Li, M., Du, X., Yi, Q. & Yan, D., Jan 26 2022, In: Science translational medicine. 14, 629, eabh2548.

  Research output: Contribution to journal › Article › peer-review

  • Hematopoietic Stem Cells 100%
  • Leukemia 82%
  • Stem Cells 74%
  • Fumarates 35%
  • Cytarabine 28%
  4 Scopus citations

• ORP4L is a prerequisite for the induction of T-cell leukemogenesis associated with human T-cell leukemia virus 1

  Zhong, W., Cao, X., Pan, G., Niu, Q., Feng, X., Xu, M., Li, M., Huang, Y., Yi, Q. & Yan, D., Feb 17 2022, In: Blood. 139, 7, p. 1052-1065 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Deltaretrovirus 100%
  • Ablation 83%
  • Adult T Cell Leukemia Lymphoma 53%
  • Oncogenic 50%
  • T-Lymphocytes 44%
  5 Scopus citations

• RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway

  Wang, Q., Lin, Z., Wang, Z., Ye, L., Xian, M., Xiao, L., Su, P., Bi, E., Huang, Y. H., Qian, J., Liu, L., Ma, X., Yang, M., Xiong, W., Zu, Y., Pingali, S. R., Xu, B. & Yi, Q., Jan 6 2022, In: Blood. 139, 1, p. 59-72 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Carfilzomib 100%
  • 2-5A-dependent ribonuclease 84%
  • carfilzomib 82%
  • Retinoic Acid 67%
  • Retinoic Acid Receptors 66%
  5 Scopus citations
• 2021

  Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma

  Li, Z., Liu, H., He, J., Wang, Z., Yin, Z., You, G., Wang, Z., Davis, R. E., Lin, P., Bergsagel, P. L., Manasanch, E. E., Wong, S. T. C., Esnaola, N. F., Chang, J. C., Orlowski, R. Z., Yi, Q. & Yang, J., Jan 5 2021, In: Cell Metabolism. 33, 1, p. 78-93.e7

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Acetate-CoA Ligase 100%
  • Carcinogenesis 45%
  • Obesity 41%
  • interferon regulatory factor-4 37%
  • Obese Mice 9%
  38 Scopus citations

• Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells

  Xue, G., Zheng, N., Fang, J., Jin, G., Li, X., Dotti, G., Yi, Q. & Lu, Y., Dec 13 2021, In: Cancer Cell. 39, 12, p. 1610-1622.e9

  Research output: Contribution to journal › Article › peer-review

  • Cell- and Tissue-Based Therapy 100%
  • Antigens 67%
  • Neoplasms 34%
  • Interferons 27%
  • Adenosine Triphosphate 23%
  18 Scopus citations

• ALCAM-EGFR interaction regulates myelomagenesis

  Luo, H., Zhang, D., Wang, F., Wang, Q., Wu, Y., Gou, M., Hu, Y., Zhang, W., Huang, J., Gong, Y., Pan, L., Li, T., Zhao, P., Zhang, D., Qu, Y., Liu, Z., Jiang, T., Dai, Y., Guo, T., Zhu, J., & 5 othersYe, L., Zhang, L., Liu, W., Yi, Q. & Zheng, Y., Dec 14 2021, In: Blood Advances. 5, 23, p. 5269-5282 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Activated-Leukocyte Cell Adhesion Molecule 100%
  • ErbB Receptors 56%
  • Signal Transduction 23%
  • Epidermal Growth Factor 19%
  • Mesenchymal Stem Cells 17%
  5 Scopus citations

• ALCAM-EGFR interaction regulates myelomagenesis

  Luo, H., Zhang, D., Wang, F., Wang, Q., Wu, Y., Gou, M., Hu, Y., Zhang, W., Huang, J., Gong, Y., Pan, L., Li, T., Zhao, P., Zhang, D., Qu, Y., Liu, Z., Jiang, T., Dai, Y., Guo, T., Zhu, J., & 5 othersYe, L., Zhang, L., Liu, W., Yi, Q. & Zheng, Y., Dec 1 2021, In: Blood Advances. 5, 23, p. 5269-5282 14 p.

  Research output: Contribution to journal › Article › peer-review

• BMI1 regulates multiple myeloma-associated macrophage’s pro-myeloma functions

  Zhang, D., Huang, J., Wang, F., Ding, H., Cui, Y., Yang, Y., Xu, J., Luo, H., Gao, Y., Pan, L., Wu, Y., Gong, Y., Xie, L., Liu, Z., Qu, Y., Zhang, L., Liu, W., Zhang, W., Zhao, S., Yi, Q., & 2 othersNiu, T. & Zheng, Y., May 2021, In: Cell Death and Disease. 12, 5, 495.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Multiple Myeloma 100%
  • Macrophages 70%
  • Bone Marrow 18%
  • Polycomb-Group Proteins 9%
  • Hedgehogs 8%
  12 Scopus citations

• CD36-mediated ferroptosis dampens intratumoral CD8⁺ T cell effector function and impairs their antitumor ability

  Ma, X., Xiao, L., Liu, L., Ye, L., Su, P., Bi, E., Wang, Q., Yang, M., Qian, J. & Yi, Q., May 4 2021, In: Cell Metabolism. 33, 5, p. 1001-1012.e5

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Ferroptosis 100%
  • T-Lymphocytes 39%
  • Tumor Microenvironment 28%
  • Neoplasms 14%
  • Cytokines 11%
  241 Scopus citations

• Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma

  Li, R., Zheng, C., Wang, Q., Bi, E., Yang, M., Hou, J., Fu, W., Yi, Q. & Qian, J., Mar 2021, In: Haematologica. 106, 3, p. 838-846 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Multiple Myeloma 100%
  • Immunotherapy 89%
  • Peptides 64%
  • T-Lymphocytes 46%
  • HLA-A*02:01 antigen 38%
  5 Scopus citations

• ORP4L is a prerequisite for the induction of T-cell leukemogenesis associated with human T-cell leukemia virus 1

  Zhong, W., Cao, X., Pan, G., Niu, Q., Feng, X., Xu, M., Li, M., Huang, Y., Yi, Q. & Yan, D., Nov 23 2021, (E-pub ahead of print) In: Blood.

  Research output: Contribution to journal › Article › peer-review

• RARγ activation sensitizes human myeloma cells to carfilzomib treatment through OAS-RNase L innate immune pathway

  Wang, Q., Lin, Z., Wang, Z., Ye, L., Xian, M., Xiao, L., Su, P., Bi, E., Huang, Y-H., Qian, J., Liu, L., Ma, X., Yang, M., Xiong, W., Zu, Y., Pingali, S. R., Xu, B. & Yi, Q., Aug 19 2021, (E-pub ahead of print) In: Blood.

  Research output: Contribution to journal › Article › peer-review

  • Carfilzomib 100%
  • 2-5A-dependent ribonuclease 84%
  • carfilzomib 82%
  • All-Trans-Retinoic Acid 50%
  • Proteasome Inhibitor 38%
• 2020

  Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study

  Chin, C. K., Lim, K. J., Lewis, K., Jain, P., Qing, Y., Feng, L., Cheah, C. Y., Seymour, J. F., Ritchie, D., Burbury, K., Tam, C. S., Fowler, N. H., Fayad, L. E., Westin, J. R., Neelapu, S. S., Hagemeister, F. B., Samaniego, F., Flowers, C. R., Nastoupil, L. J. & Dickinson, M. J., Dec 2020, In: British Journal of Haematology. 191, 5, p. 806-815 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Propensity Score 100%
  • Stem Cell Transplantation 97%
  • B-Cell Lymphoma 96%
  • Drug Therapy 36%
  • Chimeric Antigen Receptors 20%
  5 Scopus citations

• Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma

  Tseng, H. C., Xiong, W., Badeti, S., Yang, Y., Ma, M., Liu, T., Ramos, C. A., Dotti, G., Fritzky, L., Jiang, J. G., Yi, Q., Guarrera, J., Zong, W. X., Liu, C. & Liu, D., Dec 1 2020, In: Nature Communications. 11, 1, 4810.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Basigin 100%
  • Chimeric Antigen Receptors 85%
  • antigens 80%
  • cancer 59%
  • Antigen 52%
  75 Scopus citations

• Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9

  Liu, L., Bi, E., Ma, X., Xiong, W., Qian, J., Ye, L., Su, P., Wang, Q., Xiao, L., Yang, M., Lu, Y. & Yi, Q., Nov 19 2020, In: Nature Communications. 11, 1, 5902.

  Research output: Contribution to journal › Article › peer-review

  • interleukins 100%
  • Interleukin-9 85%
  • tumors 56%
  • Antitumor 54%
  • Proliferative 39%
  48 Scopus citations

• Enhanced lipid accumulation and metabolism are required for the differentiation and activation of tumor-associated macrophages

  Su, P., Wang, Q., Bi, E., Ma, X., Liu, L., Yang, M., Qian, J. & Yi, Q., Apr 1 2020, In: Cancer research. 80, 7, p. 1438-1450 13 p.

  Research output: Contribution to journal › Article › peer-review

  • Lipid Metabolism 100%
  • Macrophages 72%
  • Tumor Microenvironment 64%
  • Lipids 54%
  • Transcriptional Activation 37%
  166 Scopus citations

• Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma

  Li, R., Zheng, C., Wang, Q., Bi, E., Yang, M., Hou, J., Fu, W., Yi, Q. & Qian, J., Feb 20 2020, (E-pub ahead of print) In: Haematologica.

  Research output: Contribution to journal › Article › peer-review

  • Multiple Myeloma 100%
  • Immunotherapy 89%
  • Peptides 64%
  • T-Lymphocytes 46%
  • HLA-A*02:01 antigen 38%

• MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma

  Wang, Q., Zhao, D., Xian, M., Wang, Z., Bi, E., Su, P., Qian, J., Ma, X., Yang, M., Liu, L., Zu, Y., Pingali, S. R., Chen, K., Cai, Z. & Yi, Q., Nov 26 2020, In: Blood. 136, 22, p. 2557-2573 17 p.

  Research output: Contribution to journal › Article › peer-review

  • Proteasome Inhibitor 100%
  • Proteasome Inhibitors 79%
  • Multiple Myeloma 65%
  • Superoxide 65%
  • Biological Marker 60%
  26 Scopus citations

• Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma

  Hu, Y., Liu, H., Fang, C., Li, C., Xhyliu, F., Dysert, H., Bodo, J., Habermehl, G., Russell, B. E., Li, W., Chappell, M., Jiang, X., Ondrejka, S. L., Hsi, E. D., Maciejewski, J. P., Yi, Q., Anderson, K. C., Munshi, N. C., Ao, G., Valent, J. N., & 2 othersLin, J. & Zhao, J., May 2020, In: Cancer research. 80, 10, p. 2031-2044 14 p.

  Research output: Contribution to journal › Article › peer-review

  • Multiple Myeloma 100%
  • daratumumab 52%
  • Neoplasms 32%
  • Therapeutics 16%
  • Plasma Cells 15%
  28 Scopus citations
• 2019

  2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces peripheral blood abnormalities and plasma cell neoplasms resembling multiple myeloma in mice

  Wang, L., Kumar, M., Deng, Q., Wang, X., Liu, M., Gong, Z., Zhang, S., Ma, X., Xu-Monette, Z. Y., Xiao, M., Yi, Q., Young, K. H., Ramos, K. S. & Li, Y., Jan 1 2019, In: Cancer Letters. 440-441, p. 135-144 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Plasma Cell Neoplasms 100%
  • Polychlorinated Dibenzodioxins 79%
  • Multiple Myeloma 61%
  • Blood Cells 51%
  • Monoclonal Gammopathy of Undetermined Significance 22%
  9 Scopus citations

• CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma

  Xu, R., Li, Y., Yan, H., Zhang, E., Huang, X., Chen, Q., Chen, J., Qu, J., Liu, Y., He, J., Yi, Q. & Cai, Z., Oct 14 2019, In: Cell death & disease. 10, 10, p. 781

  Research output: Contribution to journal › Article › peer-review

  • Multiple Myeloma 100%
  • Macrophages 70%
  • Bone Marrow 22%
  • Drug Resistance 18%
  • Phenotype 12%
  32 Scopus citations

• Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment

  Ma, X., Bi, E., Lu, Y., Su, P., Huang, C., Liu, L., Wang, Q., Yang, M., Kalady, M. F., Qian, J., Zhang, A., Gupte, A. A., Hamilton, D. J., Zheng, C. & Yi, Q., Jul 2 2019, In: Cell Metabolism. 30, 1, p. 143-156.e5

  Research output: Contribution to journal › Article › peer-review

  • Tumor Microenvironment 100%
  • Cholesterol 70%
  • T-Lymphocytes 59%
  • Endoplasmic Reticulum Stress 21%
  • Neoplasms 15%
  361 Scopus citations

• MicroRNA-31-5p enhances the Warburg effect via targeting FIH

  Zhu, B., Cao, X., Zhang, W., Pan, G., Yi, Q., Zhong, W. & Yan, D., Jan 2019, In: FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 33, 1, p. 545-556 12 p.

  Research output: Contribution to journal › Article › peer-review

  • Hypoxia-Inducible Factor 1 100%
  • Glycolysis 83%
  • MicroRNAs 66%
  • MicroRNA 48%
  • A549 Cells 43%
  36 Scopus citations

• Multiple myeloma cell-derived IL-32γ increases the immunosuppressive function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression

  Yan, H., Dong, M., Liu, X., Shen, Q., He, D., Huang, X., Zhang, E., Lin, X., Chen, Q., Guo, X., Chen, J., Zheng, G., Wang, G., He, J., Yi, Q. & Cai, Z., Apr 1 2019, In: Cancer Letters. 446, p. 38-48 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Indoleamine-Pyrrole 2,3,-Dioxygenase 100%
  • Multiple Myeloma 72%
  • Immunosuppressive Agents 61%
  • Macrophages 51%
  • Myeloblastin 26%
  31 Scopus citations

• Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease

  Liu, H., He, J., Koh, S. P., Zhong, Y., Liu, Z., Wang, Z., Zhang, Y., Li, Z., Tam, B. T., Lin, P., Xiao, M., Young, K. H., Amini, B., Starbuck, M. W., Lee, H. C., Navone, N. M., Davis, R. E., Tong, Q., Bergsagel, P. L., Hou, J., & 4 othersYi, Q., Orlowski, R. Z., Gagel, R. F. & Yang, J., May 29 2019, In: Science translational medicine. 11, 494, eaau9087.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Bone Diseases 100%
  • Adipocytes 85%
  • Bone Marrow 65%
  • Peroxisomes 42%
  • Polycomb Repressive Complex 2 34%
  57 Scopus citations

• The NEDD4-1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma

  Huang, X., Gu, H., Zhang, E., Chen, Q., Cao, W., Yan, H., Chen, J., Yang, L., Lv, N., He, J., Yi, Q. & Cai, Z., Aug 7 2019, (E-pub ahead of print) In: International Journal of Cancer.

  Research output: Contribution to journal › Article › peer-review

  • Bortezomib 100%
  • Ubiquitin-Protein Ligases 93%
  • Multiple Myeloma 80%
  • Substrate Specificity 13%
  • Proteasome Endopeptidase Complex 12%
  21 Scopus citations

• TNF-α enhances Th9 cell differentiation and antitumor immunity via TNFR2-dependent pathways

  Jiang, Y., Chen, J., Bi, E., Zhao, Y., Qin, T., Wang, Y., Wang, A., Gao, S., Yi, Q. & Wang, S., Feb 4 2019, In: Journal for immunotherapy of cancer. 7, 1, 28.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Receptors, Tumor Necrosis Factor, Type II 100%
  • Immunity 58%
  • Cell Differentiation 57%
  • Receptors, Tumor Necrosis Factor, Type I 40%
  • T-Lymphocytes 26%
  37 Scopus citations
• 2018

  Cholesterol negatively regulates IL-9-producing CD8+ T cell differentiation and antitumor activity

  Ma, X., Bi, E., Huang, C., Lu, Y., Xue, G., Guo, X., Wang, A., Yang, M., Qian, J., Dong, C. & Yi, Q., Jun 4 2018, In: The Journal of experimental medicine. 215, 6, p. 1555-1569 15 p.

  Research output: Contribution to journal › Article › peer-review

  • Interleukin-9 100%
  • Cell Differentiation 56%
  • Cholesterol 51%
  • T-Lymphocytes 42%
  • Liver X Receptors 21%
  83 Scopus citations

• Correction to: miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy

  Huang, Q., Xi, J., Wang, L., Wang, X., Ma, X., Deng, Q., Lu, Y., Kumar, M., Zhou, Z., Li, L., Zeng, Z., Young, K. H., Yi, Q., Zhang, M. & Li, Y., Jul 3 2018, In: Journal of Hematology and Oncology. 11, 1, p. 90

  Research output: Contribution to journal › Article › peer-review

  • Authorship 100%
  • Immunotherapy 60%
  • T-Lymphocytes 42%
  4 Scopus citations

• Dectin-1 stimulates IL-33 expression in dendritic cells via upregulation of IRF4

  Wang, D., Gao, S., Chen, J., Zhao, Y., Jiang, Y., Chu, X., Wang, X., Liu, N., Qin, T., Yi, Q., Yue, Y. & Wang, S., Jun 2018, In: Laboratory Investigation. 98, 6, p. 708-714 7 p.

  Research output: Contribution to journal › Article › peer-review

  • interferon regulatory factor-4 100%
  • dectin 1 90%
  • Interleukin-33 80%
  • Dendritic Cells 52%
  • Up-Regulation 42%
  5 Scopus citations

• E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCs

  Bi, E., Li, R., Bover, L. C., Li, H., Su, P., Ma, X., Huang, C., Wang, Q., Liu, L., Yang, M., Lin, Z., Qian, J., Fu, W., Liu, Y-J. & Yi, Q., Nov 1 2018, In: The Journal of clinical investigation. 128, 11, p. 4821-4831 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Cadherins 100%
  • Multiple Myeloma 97%
  • Dendritic Cells 88%
  • Neoplasms 31%
  • Bone Marrow 20%
  26 Scopus citations

• IL-33 drives the antitumor effects of dendritic cells via the induction of Tc9 cells

  Liu, N., Jiang, Y., Chen, J., Nan, H., Zhao, Y., Chu, X., Wang, A., Wang, D., Qin, T., Gao, S., Yi, Q., Yue, Y. & Wang, S., Oct 1 2018, (E-pub ahead of print) In: Cellular and Molecular Immunology.

  Research output: Contribution to journal › Article › peer-review

  • Interleukin-33 100%
  • Dendritic Cells 65%
  • T-Lymphocytes 25%
  • Cancer Vaccines 25%
  • Cell Differentiation 16%
  22 Scopus citations

• Interleukin-33 contributes to the induction of Th9 cells and antitumor efficacy by Dectin-1-activated Dendritic cells

  Chen, J., Zhao, Y., Jiang, Y., Gao, S., Wang, Y., Wang, D., Wang, A., Yi, H., Gu, R., Yi, Q. & Wang, S., Jul 1 2018, In: Frontiers in immunology. 9, 01787.

  Research output: Contribution to journal › Article › peer-review

  • dectin 1 100%
  • Interleukin-33 88%
  • Dendritic Cells 58%
  • Cell Differentiation 17%
  • Foster Home Care 8%
  30 Scopus citations

• miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy

  Huang, Q., Xia, J., Wang, L., Wang, X., Ma, X., Deng, Q., Lu, Y., Kumar, M., Zhou, Z., Li, L., Zeng, Z., Young, K. H., Yi, Q., Zhang, M. & Li, Y., Apr 23 2018, In: Journal of Hematology and Oncology. 11, 1, p. 58

  Research output: Contribution to journal › Article › peer-review

  • Indoleamine-Pyrrole 2,3,-Dioxygenase 100%
  • Chimeric Antigen Receptors 99%
  • Immunotherapy 64%
  • T-Lymphocytes 45%
  • Colonic Neoplasms 37%
  90 Scopus citations

• Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma

  Hu, Y., Lin, J., Fang, H., Fang, J., Li, C., Chen, W., Liu, S., Ondrejka, S., Gong, Z., Reu, F., Maciejewski, J., Yi, Q. & Zhao, J-J., Oct 2018, In: Leukemia. 32, 10, p. 2250-2262 13 p.

  Research output: Contribution to journal › Article › peer-review

  • Adenocarcinoma of Lung 100%
  • Multiple Myeloma 92%
  • DNA Damage 81%
  • Neoplasm Metastasis 57%
  • Apoptosis 57%
  96 Scopus citations

• Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors

  Lu, Y., Wang, Q., Xue, G., Bi, E., Ma, X., Wang, A., Qian, J., Dong, C. & Yi, Q., Jun 11 2018, In: Cancer Cell. 33, 6, p. 1048-1060.e7

  Research output: Contribution to journal › Article › peer-review

  • T-Lymphocyte Subsets 100%
  • Th17 Cells 66%
  • Th1 Cells 65%
  • Aptitude 63%
  • Neoplasms 30%
  97 Scopus citations

• Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma

  Wang, Q., Lu, Y., Li, R., Jiang, Y., Zheng, Y., Qian, J., Bi, E., Zheng, C., Hou, J., Wang, S. & Yi, Q., Jan 2018, In: Leukemia. 32, 1, p. 176-183 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Colony-Stimulating Factor Receptors 100%
  • Macrophage Colony-Stimulating Factor 79%
  • Blocking Antibodies 78%
  • Multiple Myeloma 64%
  • Therapeutic Uses 54%
  54 Scopus citations

• Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease

  He, J., Chen, Q., Gu, H., Chen, J., Zhang, E., Guo, X., Huang, X., Yan, H., He, D., Yang, Y., Zhao, Y., Wang, G., He, H., Yi, Q. & Cai, Z., Aug 2018, In: Haematologica. 103, 8, p. 1369-1379 11 p.

  Research output: Contribution to journal › Article › peer-review

  • N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 100%
  • Histone Deacetylase Inhibitors 61%
  • Bone Diseases 58%
  • Therapeutic Uses 43%
  • Bone and Bones 17%
  22 Scopus citations
• 2017

  BAFF is involved in macrophage-induced bortezomib resistance in myeloma

  Chen, J., He, D., Chen, Q., Guo, X., Yang, L., Lin, X., Li, Y., Wu, W., Yang, Y., He, J., Zhang, E., Yi, Q. & Cai, Z., Nov 2 2017, In: Cell death & disease. 8, 11, p. e3161

  Research output: Contribution to journal › Article › peer-review

  • Bortezomib 100%
  • Multiple Myeloma 80%
  • Macrophages 57%
  • B-Cell Activation Factor Receptor 19%
  • B-Cell Activating Factor 17%
  18 Scopus citations

• B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

  Zhang, L., Nomie, K., Zhang, H., Bell, T., Pham, L., Kadri, S., Segal, J., Li, S., Zhou, S., Santos, D., Richard, S., Sharma, S., Chen, W., Oriabure, O., Liu, Y., Huang, S., Guo, H., Chen, Z., Tao, W., Li, C., & 13 othersWang, J., Fang, B., Wang, J., Li, L., Badillo, M., Ahmed, M., Thirumurthi, S., Huang, S. Y., Shao, Y., Lam, L., Yi, Q., Wang, Y. L. & Wang, M., Aug 1 2017, In: Clinical Cancer Research. 23, 15, p. 4212-4223 12 p.

  Research output: Contribution to journal › Article › peer-review

  • B-Cell Lymphoma 100%
  • Drug Discovery 99%
  • Heterografts 86%
  • PCI 32765 66%
  • Therapeutics 15%
  41 Scopus citations

• Dectin-1 signaling inhibits osteoclastogenesis via IL-33-induced inhibition of NFATc1

  Zhu, X., Zhao, Y., Jiang, Y., Qin, T., Chen, J., Chu, X., Yi, Q., Gao, S. & Wang, S., Aug 8 2017, In: Oncotarget. 8, 32, p. 53366-53374 9 p.

  Research output: Contribution to journal › Article › peer-review

  • dectin 1 100%
  • Interleukin-33 88%
  • NFATC Transcription Factors 86%
  • Osteoclasts 67%
  • curdlan 65%

• Dectin-1 signaling inhibits osteoclastogenesis via IL-33-induced inhibition of NFATc1

  Zhu, X., Zhao, Y., Jiang, Y., Qin, T., Chen, J., Chu, X., Yi, Q., Gao, S. & Wang, S., Jun 8 2017, In: Oncotarget. 8, 32, p. 53366-53374 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • dectin 1 100%
  • Interleukin-33 88%
  • NFATC Transcription Factors 86%
  • Osteoclasts 67%
  • curdlan 65%
  16 Scopus citations

• Foxo1 and Foxp1 play opposing roles in regulating the differentiation and antitumor activity of TH9 cells programmed by IL-7

  Bi, E., Ma, X., Lu, Y., Yang, M., Wang, Q., Xue, G., Qian, J., Wang, S. & Yi, Q., Oct 10 2017, In: Science signaling. 10, 500

  Research output: Contribution to journal › Article › peer-review

  • Interleukin-9 100%
  • Interleukin-7 89%
  • Helper-Inducer T-Lymphocytes 72%
  • Antitumor 64%
  • Histone 49%
  38 Scopus citations

• Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function

  Lee, Y. H., Martin-Orozco, N., Zheng, P., Li, J., Zhang, P., Tan, H., Park, H. J., Jeong, M., Chang, S. H., Kim, B. S., Xiong, W., Zang, W., Guo, L., Liu, Y., Dong, Z. J., Overwijk, W. W., Hwu, P., Yi, Q., Kwak, L., Yang, Z., & 6 othersMak, T. W., Li, W., Radvanyi, L. G., Ni, L., Liu, D. & Dong, C., Aug 1 2017, In: Cell Research. 27, 8, p. 1034-1045 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphocytes 100%
  • Growth 72%
  • Neoplasms 46%
  • T-Lymphocytes 17%
  • Antibodies 16%
  201 Scopus citations
• 2016

  Dectin-1-activated dendritic cells: A potent Th9 cell inducer for tumor immunotherapy

  Chen, J., Zhao, Y., Chu, X., Lu, Y., Wang, S. & Yi, Q., Nov 1 2016, In: OncoImmunology. 5, 11, e1238558.

  Research output: Contribution to journal › Article › peer-review

  • dectin 1 100%
  • Helper-Inducer T-Lymphocytes 67%
  • Dendritic Cells 58%
  • Immunotherapy 57%
  • Interleukin-9 31%
  10 Scopus citations

• Dectin-1-activated dendritic cells trigger potent antitumour immunity through the induction of Th9 cells

  Zhao, Y., Chu, X., Chen, J., Wang, Y., Gao, S., Jiang, Y., Zhu, X., Tan, G., Zhao, W., Yi, H., Xu, H., Ma, X., Lu, Y., Yi, Q. & Wang, S., Aug 5 2016, In: Nature Communications. 7, 12368.

  Research output: Contribution to journal › Article › peer-review

  • dectin 1 100%
  • immunity 75%
  • Antitumor 60%
  • induction 59%
  • Dendritic Cells 58%
  82 Scopus citations